Cord Blood News 10.17 May 3, 2018 | |
| |
TOP STORYScientists found that human umbilical cord MSC-conditioned medium promotes EMT, invasion, and migration, yet inhibits proliferation and promotes apoptosis of lung cancer cells. [Cancer Lett] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)High concentration glucose elicited human umbilical cord blood (hUCB)-derived MSC migration compared to normal glucose and high glucose-pretreated hUCB-MSC transplantation into the wound sites in mice accelerated skin wound repair. [Cell Physiol Biochem] Full Article Scientists selected and purified three different hematopoietic cell populations: hematopoietic stem cells, myeloid progenitor cells, and erythroid progenitor cells, obtained directly from fresh human umbilical cord blood units or generated in vitro under particular culture conditions. They, then, compared their functional integrity in vitro and their gene expression profiles. [Stem Cells Transl Med] Full Article As amniotic fluid is composed of fetal urine harboring MSCs, investigators hypothesized that third-trimester amniotic fluid could be a novel source of renal progenitor and differentiated cells. [Stem Cell Res Ther] Full Article Cytotoxicity of Radiocontrast Dyes in Human Umbilical Cord Mesenchymal Stem Cells The authors investigated the cytotoxic effects of two clinically used radiocontrast dyes, iohexol and iopamidol, on bone marrow and human umbilical cord MSCs. Exposure to these dyes significantly affected morphology of MSCs from both sources, as treated cells appeared transparent and no longer fibroblastoid. [Toxicol Appl Pharmacol] Abstract Freshly prepared nonirradiated and 2-Gy X-irradiated human CD34+ cells from placental umbilical cord blood were cultured with a combination of romiplostim (RP) and various cytokines. As a result, the effect of RP on cell proliferation of nonirradiated CD34+ cells was found to be comparable to that of thrombopoietin. [J Interferon Cytokine Res] Abstract | |
| |
REVIEWSMesenchymal Stem Cells on Horizon: A New Arsenal of Therapeutic Agents MSCs can be considered as an arsenal of natural bioreactors in variety of therapeutic agents. MSCs inherently express various important therapeutic agents such as growth factors and cytokines that can be manufactured, handled and stored as a prepared-to-go biologic product. [Stem Cell Rev] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSAmgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending a label variation for KYPROLIS® to include the final overall survival data from the Phase III ASPIRE trial. [Amgen] Press Release Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia Cellectis announced that the company has submitted an Investigational New Drug (IND) application to the FDA requesting approval to initiate a Phase I clinical trial for UCART22, Cellectis’ second wholly controlled TALEN® gene-edited product candidate, for the treatment of B-cell acute lymphoblastic leukemia in adult patients. [Cellectis] Press Release Novartis announced the FDA has approved Kymriah® suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. [Novartis] Press Release Pfizer Inc. announced that the European Commission has approved MYLOTARG™ in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia. [Pfizer Inc.] Press Release | |
| |
POLICY NEWSNature Announces New Editor-in-Chief Nature has named Magdalena Skipper as its new editor-in-chief. She is the first woman to hold the post. Skipper, who is currently editor-in-chief of the open-access journal Nature Communications, will become the eighth editor of Nature. [Nature News] Editorial Big UK Science Funder Says Report Harassment or Risk Losing Funding One of the world’s largest research-funding charities is cracking down on harassment and bullying. Scientists who have been sanctioned by their institutions could lose out on funding from the Wellcome Trust, under rules announced. [Nature News] Editorial Nature Journals Formalize Ethical Standards for Human Embryo and Stem-Cell Research Nature journals encourage stem-cell scientists to embrace guidelines agreed in 2016 by the International Society for Stem Cell Research as they design, execute and report their research. [Nature News] Editorial Accused Cancer Scientist Resigns as Editor of Prestigious Journal Inder Verma, the prominent cancer scientist and geneticist who has been accused of sexual harassment by several women, resigned yesterday as editor-in-chief of the Proceedings of the National Academy of Sciences, a prestigious academic journal. [ScienceInsider] Editorial
| |
EVENTSNEW 4th European Platelet Network (EUPLAN) Conference 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Leukemia (Oslo Universitetssykehus HF) NEW Postdoctoral Fellow – B-Cell Lymphoma (University of Texas Health Science Center) NEW Postdoctoral Fellow – Hematopoiesis and Leukemia (University of Pennsylvania) Research Fellow – Hematology, Blood Disorders and Stem Cell Biology (New York Blood Center) Postdoctoral Position – Chronic Lymphocytic Leukemia (Università della Svizzera italiana) Postdoctoral Fellow – Molecular and Translational Cancer Biology (Thomas Jefferson University) Postdoctoral Position – Hematology (Yale Cancer Center) Pathology Faculty Tenure Track – Leukemia and Hematopoiesis (University of Virginia) Postdoctoral Scholar – Hematology (Huntsman Cancer Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|